Last updated: November 2, 2026
BIVIGAM is a plasma-derived intravenous immune globulin, or IVIG, marketed by ADMA Biologics for primary humoral immunodeficiency disease. Its commercial outlook is driven more by IVIG demand, plasma availability, manufacturing capacity, reimbursement, and ADMA’s product portfolio than by conventional small-molecule patent protection. BIVIGAM-specific revenue is not separately reported, so financial analysis relies on ADMA’s consolidated results for BIVIGAM, ASCENIV, Nabi-HB, and related products.
ADMA’s consolidated revenue increased from approximately $229 million in 2022 to about $301 million in 2023 and approximately $404 million in 2024. The company moved from operating losses to sustained profitability as utilization, pricing, manufacturing scale, and plasma supply improved.[1][2]
What is BIVIGAM and how is it used?
BIVIGAM is a 10% human normal immunoglobulin solution for intravenous administration. The FDA approved it on Dec. 19, 2012, under biologics license application No. 125399 for the treatment of primary humoral immunodeficiency disease in adults and adolescents.[3]
| Attribute |
BIVIGAM |
| Active ingredient |
Human normal immunoglobulin |
| Dosage form |
10% intravenous solution |
| Administration |
Intravenous infusion |
| FDA approval |
Dec. 19, 2012 |
| Approved use |
Primary humoral immunodeficiency disease |
| Sponsor |
ADMA Biologics |
| BLA |
125399 |
| Product type |
Plasma-derived biologic |
| Primary commercial market |
Immune globulin replacement therapy |
BIVIGAM is manufactured from human plasma collected from U.S. donors. The product’s commercial value depends on the ability to secure qualified plasma, maintain viral-reduction controls, release batches consistently, and supply hospitals, specialty pharmacies, physicians, and distributors.
What is the FDA regulatory status of BIVIGAM?
BIVIGAM remains an FDA-approved biologic marketed under BLA 125399. ADMA expanded its commercial infrastructure after acquiring and rebuilding the product’s manufacturing and supply operations. The current commercial strategy positions BIVIGAM as one of three revenue-generating products alongside ASCENIV and Nabi-HB.[1]
BIVIGAM is not an interchangeable biosimilar. It is an originator biologic with a plasma-derived manufacturing process. A competing product would generally require a biologics license or biosimilar application under the Public Health Service Act rather than a conventional abbreviated new drug application.
How does BIVIGAM compare with competing IVIG products?
BIVIGAM competes in the U.S. IVIG market with products including:
| Product |
Company |
General market position |
| BIVIGAM |
ADMA Biologics |
Primary immunodeficiency replacement therapy |
| ASCENIV |
ADMA Biologics |
Immune globulin product for primary immunodeficiency |
| Gammagard Liquid |
Takeda |
Large-scale IVIG franchise |
| Gamunex-C |
Grifols |
Broad IVIG and subcutaneous immunoglobulin franchise |
| Privigen |
CSL Behring |
Major hospital and specialty IVIG product |
| Octagam |
Octapharma |
IVIG replacement and immune-modulating product |
| Panzyga |
Octapharma |
Competing IVIG product |
| Flebogamma DIF |
Grifols |
Plasma-derived immunoglobulin product |
The principal competitive factors are supply reliability, payer access, hospital contracting, infusion tolerability, physician familiarity, distributor inventory, and manufacturing capacity. Product differentiation is narrower than in many specialty biologic markets because many IVIG products share the same broad replacement-therapy role.
When does BIVIGAM lose regulatory exclusivity?
BIVIGAM’s 12-year reference-product exclusivity period under the U.S. biosimilar framework ran from the Dec. 19, 2012 approval date to Dec. 19, 2024.[3][4]
| Exclusivity category |
BIVIGAM status |
| FDA approval date |
Dec. 19, 2012 |
| Estimated 12-year reference-product exclusivity end |
Dec. 19, 2024 |
| Orphan-drug exclusivity |
Not identified as the primary BIVIGAM exclusivity mechanism |
| Small-molecule generic exclusivity |
Not applicable |
| Biosimilar pathway |
Legally available after the statutory reference-product period, subject to FDA requirements |
Loss of the 12-year reference-product period does not create automatic biosimilar entry. A competitor still must develop a qualifying product, obtain sufficient comparability data, address manufacturing and clinical requirements, and manage the commercial difficulty of obtaining plasma.
What patents protect BIVIGAM?
BIVIGAM does not have the same Orange Book patent framework used for small-molecule drugs. Biologics generally rely on the Purple Book, FDA exclusivity periods, BLA rights, process patents, formulation patents, manufacturing know-how, trade secrets, and regulatory barriers.
| Patent and regulatory issue |
BIVIGAM position |
| Orange Book listing |
Not the principal listing mechanism for BIVIGAM |
| Purple Book reference product |
Relevant because BIVIGAM is licensed under a BLA |
| Product-specific composition patent |
No publicly established Orange Book-style listing identified |
| Manufacturing patents |
Potentially relevant to plasma processing, purification, viral reduction, and formulation |
| Trade secrets |
Material, particularly for process controls and batch consistency |
| Biosimilar litigation framework |
Governed by the Biologics Price Competition and Innovation Act |
ADMA’s public filings describe intellectual property covering plasma-derived products, manufacturing processes, formulations, purification, viral inactivation, and related technologies. The economic strength of that estate is difficult to measure from BIVIGAM alone because ADMA does not publicly allocate individual patents or revenue by product.[1]
What formulation patents protect BIVIGAM?
BIVIGAM’s formulation is a 10% immunoglobulin solution. Potentially relevant technical protections can include protein concentration, stabilizers, pH control, excipients, aggregation control, filtration, viral inactivation, and storage stability.
No public record establishes that a single formulation patent prevents competition with BIVIGAM. A competing IVIG manufacturer could seek approval for a different formulation and manufacturing process, reducing the practical value of any narrow formulation claim.
Are there BIVIGAM method-of-use patents?
BIVIGAM’s approved use is primary humoral immunodeficiency disease. The approval does not create an exclusive therapeutic market after the 12-year reference-product exclusivity period. A method-of-use patent could protect a narrower dosing regimen, patient population, or treatment method, but no publicly established BIVIGAM-specific method-of-use patent is the central commercial barrier.
How many patents cover BIVIGAM?
A reliable product-level patent count is not available from the FDA labeling record or ADMA’s public financial disclosures. The company reports its intellectual property portfolio at the corporate or platform level rather than assigning every patent to BIVIGAM.
The more important protection layers are:
- FDA biologic licensure.
- Reference-product exclusivity.
- Manufacturing know-how.
- Plasma collection infrastructure.
- Quality systems and regulatory history.
- Supply contracts and distribution access.
- Potential process and formulation patents.
For IVIG, process execution can be more difficult to replicate than the written composition. A competitor must source sufficient plasma, operate validated fractionation and purification systems, demonstrate viral safety, and build a commercially reliable supply chain.
Has BIVIGAM faced Paragraph IV challenges or patent litigation?
BIVIGAM is not normally challenged through a Paragraph IV ANDA certification because it is a biologic rather than a conventional small-molecule drug. The relevant competitive pathway is biosimilar development under the Public Health Service Act.
No publicly reported BIVIGAM-specific Paragraph IV litigation is identified in the FDA approval materials or ADMA’s principal public disclosures cited here. The absence of an ANDA challenge does not eliminate competitive risk. A biosimilar sponsor could pursue a separate BLA and later engage in patent litigation under the biologics patent-dispute framework.
No major publicly disclosed BIVIGAM settlement agreement has been identified in the cited records. A future settlement could establish a negotiated launch date for a biosimilar, but no such date is currently part of BIVIGAM’s public commercial record.
What is the financial trajectory of BIVIGAM’s manufacturer?
ADMA’s financial trajectory has improved sharply since the company expanded commercial production and increased plasma collection capacity.
| Fiscal year |
ADMA consolidated revenue |
Financial direction |
| 2022 |
Approximately $229 million |
Revenue growth, continued investment in capacity |
| 2023 |
Approximately $301 million |
Stronger product demand and operating leverage |
| 2024 |
Approximately $404 million |
Further growth and improved profitability |
Sources: ADMA Biologics annual and quarterly filings and earnings releases.[1][2]
These figures are consolidated and do not represent BIVIGAM alone. ADMA does not report BIVIGAM revenue as a separate segment. Product-level revenue exposure therefore cannot be calculated directly from public filings.
BIVIGAM contributes to a broader revenue base that includes ASCENIV and Nabi-HB. This reduces the financial impact of any single-product disruption but also makes it impossible to isolate BIVIGAM’s contribution to consolidated growth without company-provided product sales data.
What is driving ADMA’s revenue growth?
The main drivers are:
- Higher IVIG demand from patients requiring immunoglobulin replacement.
- Increased production and plasma collection capacity.
- Improved product availability after earlier operational constraints.
- Better absorption of fixed manufacturing costs.
- Expansion of commercial distribution.
- Continued need for immune globulin products across specialty and hospital channels.
ADMA’s operating leverage is important because plasma-derived products carry high fixed costs. Once plasma procurement, manufacturing, testing, and facility costs are covered, incremental product volume can improve gross margin disproportionately.
What market dynamics affect BIVIGAM?
Plasma supply is the core supply constraint
IVIG manufacturers depend on large volumes of human plasma. Collection volumes can be affected by donor compensation, collection-center throughput, labor availability, regulatory requirements, weather events, public-health conditions, and competition for donors.
ADMA has invested in plasma collection infrastructure to support its products. Vertical integration can improve supply visibility, but it also requires capital, regulatory compliance, staffing, donor recruitment, and operating discipline.
IVIG demand remains structurally durable
Primary immunodeficiency patients generally require repeated or lifelong replacement therapy. This creates recurring demand rather than one-time treatment revenue. Demand can also be supported by increased diagnosis, improved survival, greater awareness of immune deficiencies, and broader access to specialty care.
The market is competitive, but treatment substitution can be limited when physicians and patients prioritize consistent supply, tolerability, reimbursement, and continuity of therapy.
Pricing is controlled by reimbursement and contracting
BIVIGAM’s realized price depends on payer contracts, hospital purchasing arrangements, specialty-distribution margins, government reimbursement, site-of-care economics, and infusion-provider negotiations. List price increases alone do not determine net revenue.
Hospital and specialty-pharmacy buyers can shift volume among IVIG suppliers when products are clinically substitutable. Supply shortages can temporarily improve demand for available products, but that benefit can reverse when competing inventory returns.
What generic or biosimilar launch risks exist for BIVIGAM?
BIVIGAM faces lower near-term generic risk than a small-molecule drug because a conventional ANDA route is not available. Its long-term biosimilar risk is real but operationally complex.
| Risk factor |
Effect on BIVIGAM |
| Expired 12-year reference exclusivity |
Permits biosimilar development and approval pathways |
| Lack of automatic substitution |
Limits immediate pharmacy-level switching |
| Plasma collection requirements |
Raises entry costs |
| Manufacturing validation |
Creates technical and regulatory barriers |
| Hospital contracting |
Can accelerate or slow share loss |
| Physician familiarity |
Supports incumbent retention |
| IVIG supply shortages |
Can protect incumbent demand |
| Multiple established competitors |
Increases pricing pressure |
A biosimilar would likely enter through specialty distribution, hospital contracting, and payer formularies rather than through immediate automatic substitution at retail pharmacies. The commercial impact would depend on interchangeability status, supply reliability, discounts, and clinical adoption.
How strong is the BIVIGAM patent estate?
BIVIGAM’s effective protection is moderate to strong against rapid entry but weaker against long-term biosimilar competition.
Its strongest barriers are operational and regulatory:
- Plasma access.
- Manufacturing scale.
- Viral safety validation.
- FDA compliance history.
- Distribution relationships.
- Recurring patient demand.
- Physician and provider familiarity.
Its weaker barriers are traditional product exclusivity and clearly identifiable composition patents. The 12-year reference-product exclusivity period has expired, and no Orange Book-style patent wall provides an obvious long-duration barrier.
The practical conclusion is that BIVIGAM is protected primarily by manufacturing complexity and market execution rather than by a simple, high-value patent claim.
What is BIVIGAM’s geographic coverage?
BIVIGAM’s principal commercial market is the United States. ADMA’s operating model is centered on U.S. plasma collection, U.S. manufacturing, and U.S. regulatory approval.
International expansion would require country-specific product registrations, manufacturing and pharmacovigilance compliance, reimbursement access, distribution partners, and potentially different plasma-origin requirements. No broad international revenue base for BIVIGAM is established in ADMA’s primary public disclosures.
What licensing deals affect BIVIGAM?
BIVIGAM was originally developed and commercialized before ADMA’s current growth phase. ADMA’s present economics are more closely tied to internal manufacturing, plasma collection, and commercial operations than to a publicly disclosed external licensing royalty stream.
No major current licensing transaction is identified in the cited public filings as a principal driver of BIVIGAM revenue. ADMA’s reported results emphasize product sales, plasma operations, manufacturing capacity, and portfolio execution.
What are the likely BIVIGAM launch scenarios for competitors?
Base case: no immediate biosimilar launch
BIVIGAM continues to compete against established IVIG products, with ADMA relying on supply reliability and manufacturing scale. Revenue grows with market demand and capacity.
Moderate-risk case: one biosimilar entrant
A biosimilar or follow-on IVIG product enters through selected payers or hospital systems. Price discounts increase, but BIVIGAM retains volume through physician familiarity, supply continuity, and existing contracts.
High-risk case: multiple entrants and excess supply
Several competing products reach the market while plasma supply improves. Payers use formulary pressure and contracting to reduce net prices. BIVIGAM could experience slower volume growth, lower pricing, and reduced gross margin.
Supply-constrained case
A shortage affects one or more competitors. BIVIGAM benefits from available inventory, but ADMA must maintain quality and production consistency to convert temporary demand into durable contracts.
Key Takeaways
- BIVIGAM is a 10% plasma-derived IVIG product approved in 2012 for primary humoral immunodeficiency.
- Its 12-year U.S. reference-product exclusivity period ended in December 2024.
- BIVIGAM is not an Orange Book small-molecule product and has no conventional Paragraph IV exposure.
- No publicly established BIVIGAM-specific patent count or patent-expiration wall is disclosed.
- The main barriers are plasma supply, manufacturing validation, viral safety, regulatory compliance, and distribution access.
- ADMA’s consolidated revenue increased from approximately $229 million in 2022 to approximately $404 million in 2024.
- BIVIGAM-specific revenue is not separately reported.
- Biosimilar risk is lower than conventional generic risk but could increase after regulatory exclusivity ended.
- ADMA’s financial performance depends on BIVIGAM, ASCENIV, Nabi-HB, plasma availability, production scale, and reimbursement.
- The strongest commercial defense is reliable supply rather than a clearly disclosed long-duration product patent.
FAQs
Is BIVIGAM a biosimilar?
No. BIVIGAM is an FDA-licensed plasma-derived biologic marketed under BLA 125399. It is not a biosimilar to another IVIG product.
Can a generic version of BIVIGAM be approved through an ANDA?
Generally, no. A competing product would normally require a biologics license or biosimilar pathway rather than a conventional ANDA.
Does BIVIGAM have Orange Book patents?
BIVIGAM is not principally protected through Orange Book listing. Its relevant protections arise from biologic exclusivity, manufacturing patents, process know-how, regulatory barriers, and supply infrastructure.
Is BIVIGAM revenue disclosed separately by ADMA?
No. ADMA reports consolidated product revenue rather than a separate BIVIGAM revenue line.
What is the biggest commercial risk to BIVIGAM?
The largest risks are biosimilar or follow-on competition after loss of reference-product exclusivity, IVIG price pressure, plasma supply disruption, manufacturing problems, and payer or hospital contracting losses.
References
-
ADMA Biologics, Inc. (2025). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
ADMA Biologics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2012). BIVIGAM prescribing information and biologics license application No. 125399. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.
